[Disease-modifying antirheumatic drug and malignant diseases : Carol Nachman Symposium 2025]

When people suffering from cancer additionally have a rheumatic inflammatory disease, there is always the worry that due to the treatment, which in the broadest sense works on the immune system, could increase the probability of a recurrence of the tumor or a second malignancy. The choice of the most suitable disease-modifying antirheumatic drug then becomes difficult. Most recently, for this complex question the meaningful recommendations or so-called points to consider (PTC) of the European Alliance of Associations for Rheumatology (EULAR) can be referred to.